[The safety and efficacy of alimemazine (teraligen) in relieving anxiety in patients with alcohol addiction].

Autor:	Asadullin AR; Bashkir State Medical University, Ufa, Russia., Yuldashev VL; Bashkir State Medical University, Ufa, Russia., Asadullina GM; Akmully Bashkir State Pedagogic University, Ufa, Russia., Akhmetova EA; Bashkir State Medical University, Ufa, Russia., Ishchenko KA; Corporation 'Valenta Pharmaceuticals', Moscow, Russia.
Jazyk:	ruština
Zdroj:	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2018; Vol. 118 (1. Vyp. 2), pp. 39-44.
DOI:	10.17116/jnevro20181181239-44
Abstrakt:	Aim: To assess the efficacy of monotherapy of anxiety in alcoholism with alimemazine (teraligen). Material and Methods: Thirty-six patients with alcohol addiction were treated with alimemazine in dose 15 mg during 9 month. In control group (11 patients) teraligen was no used. Results and Conclusion: A significant positive effect of treatment with teraligen was observed. There were the improvement in alcohol addiction course, decrease in scores on the Addiction Severity Index (ASI) from severe to mild level and decrease in trait and state anxiety measured with the Spielberger-Khanin scale from high to low levels. The reduction on symptoms of depression from moderate (at baseline) to subdepressive levels on the Beck Depression Inventory was noted in the end of treatment.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu